0001179110-20-004829.txt : 20200410 0001179110-20-004829.hdr.sgml : 20200410 20200410172956 ACCESSION NUMBER: 0001179110-20-004829 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200408 FILED AS OF DATE: 20200410 DATE AS OF CHANGE: 20200410 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MCLAUGHLIN KEVIN F CENTRAL INDEX KEY: 0001214938 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36065 FILM NUMBER: 20787551 MAIL ADDRESS: STREET 1: C/O ACCELERON PHARMA INC. STREET 2: 128 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ACCELERON PHARMA INC CENTRAL INDEX KEY: 0001280600 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 128 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-649-9200 MAIL ADDRESS: STREET 1: 128 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 edgar.xml FORM 4 - X0306 4 2020-04-08 0 0001280600 ACCELERON PHARMA INC XLRN 0001214938 MCLAUGHLIN KEVIN F 128 SIDNEY STREET CAMBRIDGE MA 02139 0 1 0 0 SVP, CFO and Treasurer Common Stock 2020-04-08 4 M 0 4000 24.11 A 15216 D Common Stock 2020-04-08 4 M 0 12774 41.20 A 27990 D Common Stock 2020-04-08 4 M 0 10000 27.97 A 37990 D Common Stock 2020-04-08 4 M 0 10000 30.17 A 47990 D Common Stock 2020-04-08 4 S 0 2900 82.83 D 45090 D Common Stock 2020-04-08 4 S 0 5037 83.68 D 40053 D Common Stock 2020-04-08 4 S 0 3803 84.89 D 36250 D Common Stock 2020-04-08 4 S 0 15410 85.80 D 20840 D Common Stock 2020-04-08 4 S 0 5921 86.79 D 14919 D Common Stock 2020-04-08 4 S 0 3703 87.50 D 11216 D Common Stock 2020-04-09 4 M 0 17226 41.20 A 28442 D Common Stock 2020-04-09 4 S 0 17226 88.19 D 11216 D Option to Purchase Common Stock 24.11 2020-04-08 4 M 0 4000 0 D 2023-12-05 Common Stock 4000 0 D Option to Purchase Common Stock 41.20 2020-04-08 4 M 0 12774 0 D 2025-01-08 Common Stock 12774 28226 D Option to Purchase Common Stock 27.97 2020-04-08 4 M 0 10000 0 D 2026-03-03 Common Stock 10000 8300 D Option to Purchase Common Stock 30.17 2020-04-08 4 M 0 10000 0 D 2017-03-02 Common Stock 10000 31300 D Option to Purchase Common Stock 41.20 2020-04-09 4 M 0 17226 0 D 2025-01-08 Common Stock 17226 11000 D The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.19 to $83.13 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.20 to $84.13 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.23 to $85.22 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.26 to $86.21 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.31 to $87.30 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (6) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.31 to $88.03 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (7) to this Form 4. The shares of common stock underlying this stock option award vested in equal quarterly installments over the four years after the grant. The shares of common stock underlying this stock option award vested in equal quarterly installments over the four years after January 1, 2016. The shares of common stock underlying this stock option award vest in equal quarterly installments over the four years after January 1, 2017. /s/ Adam M. Veness, as attorney-in-fact for Kevin F. McLaughlin 2020-04-10